Hyperthermia as a treatment for bladder cancer
/in Hyperthermia, International Publications /von 2010-11-15 / Oncology (Williston Park, N.Y.) 2010 Nov;24(12):1149-55Hyperthermia and intravesical therapy: emerging one-two punch for bladder cancer?
/in Hyperthermia, International Publications /von 2010-11-15 / Oncology (Williston Park, N.Y.) 2010 Nov;24(12):1161, 1166Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy
/in Breast Cancer, Hyperthermia, International Publications /von 2010-11-11 / Radiother Oncol 2010 Dec;97(3):535-40Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-60An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine
/in Breast Cancer, Dendritic Cells, International Publications /von 2010-11-11 / Cancer Immunol. Immunother. 2011 Jan;60(1):87-97Hyperthermia enhances the effect of β-lapachone to cause γH2AX formations and cell death in human osteosarcoma cells
/in Hyperthermia, International Publications /von 2010-11-11 / Int J Hyperthermia 2011;27(1):53-62NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment
/in Hyperthermia, International Publications /von 2010-11-08 / Proc. Natl. Acad. Sci. U.S.A. 2010 Nov;107(47):20477-82Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells
/in Colorectal Cancer, Hyperthermia, International Publications /von 2010-11-08 / Strahlenther Onkol 2010 Nov;186(11):587-99Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
/in International Publications, Newcastle Disease Virus /von 2010-11-04 / Head Neck 2011 Oct;33(10):1394-9
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de